{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:22Z","timestamp":1740144142359,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immunosuppression in transplantation continues to be associated with a multitude of adverse effects. Induction of immune tolerance may be a viable strategy to reduce dependence on immunosuppression. Various trials are currently underway to assess the efficacy of this strategy. However, long-term safety data for these immune tolerance regimes has yet to be established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>At the completion of primary follow-up of various Medeor kidney transplant studies, subjects receiving cellular immunotherapy products will be followed annually as per protocolized schedule for up to an additional 84\u00a0months (7\u00a0years) to evaluate long-term safety. Long-term safety will be assessed by summarizing incidence of serious adverse events, adverse events leading to study withdrawal and hospitalization rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This extension study will be an important step in evaluating safety issues pertaining to immune tolerance regimens, long-term effects of which are largely unknown. These data are essential for furthering an unrealized goal of kidney transplantation- graft longevity without the adverse effects from long-term immunosuppression. The study design utilizes the methodology of a master protocol, wherein multiple therapies can be assessed simultaneously with accompanied gathering of long-term safety data.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07204-4","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:23:05Z","timestamp":1679862185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor\u2019s cellular immunotherapy products: the MDR-105-SAE"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5863-3562","authenticated-orcid":false,"given":"Sam","family":"Kant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dixon B.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenuta","family":"Micsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"issue":"5","key":"7204_CR1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1600-6143.2012.03992.x","volume":"12","author":"JD Scandling","year":"2012","unstructured":"Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012;12(5):1133\u201345. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.03992.x (https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1600-6143.2012.03992.x).","journal-title":"Am J Transplant"},{"issue":"3","key":"7204_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/ajt.13091","volume":"15","author":"JD Scandling","year":"2015","unstructured":"Scandling JD, Busque S, Shizuru JA, et al. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant. 2015;15(3):695\u2013704. https:\/\/doi.org\/10.1111\/ajt.13091 (https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/ajt.13091).","journal-title":"Am J Transplant"},{"issue":"528","key":"7204_CR3","doi-asserted-by":"publisher","first-page":"aax8863","DOI":"10.1126\/scitranslmed.aax8863","volume":"12","author":"S Busque","year":"2020","unstructured":"Busque S, Scandling JD, Lowsky R, et al. Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Sci Transl Med. 2020;12(528):aax8863. https:\/\/doi.org\/10.1126\/scitranslmed.aax8863 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31996467).","journal-title":"Sci Transl Med."},{"key":"7204_CR4","doi-asserted-by":"publisher","first-page":"791725","DOI":"10.3389\/fimmu.2021.791725","volume":"12","author":"MA Podest\u00e0","year":"2021","unstructured":"Podest\u00e0 MA, Sykes M. Chimerism-based tolerance to kidney allografts in humans: novel insights and future perspectives. Front Immunol. 2021;12:791725. https:\/\/doi.org\/10.3389\/fimmu.2021.791725 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35069574).","journal-title":"Front Immunol."},{"issue":"1","key":"7204_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/TP.0b013e3182782fc1","volume":"95","author":"J Leventhal","year":"2013","unstructured":"Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation. 2013;95(1):169\u201376. https:\/\/doi.org\/10.1097\/TP.0b013e3182782fc1 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23222893).","journal-title":"Transplantation"},{"issue":"5","key":"7204_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.humimm.2018.01.002","volume":"79","author":"JD Scandling","year":"2018","unstructured":"Scandling JD, Busque S, Lowsky R, et al. Macrochimerism and clinical transplant tolerance. Hum Immunol. 2018;79(5):266\u201371. https:\/\/doi.org\/10.1016\/j.humimm.2018.01.002.","journal-title":"Hum Immunol"},{"issue":"5","key":"7204_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.humimm.2017.11.008","volume":"79","author":"H Sasaki","year":"2018","unstructured":"Sasaki H, Oura T, Spitzer TR, et al. Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. Hum Immunol. 2018;79(5):258\u201365. https:\/\/doi.org\/10.1016\/j.humimm.2017.11.008.","journal-title":"Hum Immunol"},{"issue":"1","key":"7204_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ajt.16139","volume":"21","author":"F Issa","year":"2021","unstructured":"Issa F, Strober S, Leventhal JR, et al. The fourth international workshop on clinical transplant tolerance. Am J Transp. 2021;21(1):21\u201331. https:\/\/doi.org\/10.1111\/ajt.16139.","journal-title":"Am J Transp"},{"issue":"5","key":"7204_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","volume":"8","author":"DP Steensma","year":"2018","unstructured":"Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018;8(5):47\u20137. https:\/\/doi.org\/10.1038\/s41408-018-0085-4 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29795386).","journal-title":"Blood Cancer J"},{"issue":"1","key":"7204_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/TP.0b013e318293fcf8","volume":"96","author":"M First","year":"2013","unstructured":"First M, Dhadda S, Croy R, Holman J, Fitzsimmons W. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. Transplantation. 2013;96(1):58\u201364. https:\/\/doi.org\/10.1097\/TP.0b013e318293fcf8 (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23619735).","journal-title":"Transplantation"},{"issue":"16","key":"7204_CR11","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","volume":"69","author":"R Marcen","year":"2009","unstructured":"Marcen R. Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69(16):2227\u201343. https:\/\/doi.org\/10.2165\/11319260-000000000-00000 (http:\/\/www.ingentaconnect.com\/content\/adis\/dgs\/2009\/00000069\/00000016\/art00004).","journal-title":"Drugs"},{"issue":"8","key":"7204_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMra011295","volume":"346","author":"M Pascual","year":"2002","unstructured":"Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346(8):580\u201390. https:\/\/doi.org\/10.1056\/NEJMra011295 (http:\/\/content.nejm.org\/cgi\/content\/extract\/346\/8\/580).","journal-title":"N Engl J Med"},{"issue":"1","key":"7204_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s43441-021-00322-8","volume":"56","author":"M Burcu","year":"2021","unstructured":"Burcu M, Manzano-Salgado CB, Butler AM, Christian JB. A framework for extension studies using real-world data to examine long-term safety and effectiveness. Ther Innov Regul Sci. 2021;56(1):15\u201322. https:\/\/doi.org\/10.1007\/s43441-021-00322-8.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"7204_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62\u201370. https:\/\/doi.org\/10.1056\/NEJMra1510062.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07204-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07204-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07204-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:23:38Z","timestamp":1679862218000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07204-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7204"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07204-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DCB is a paid consultant to Medeor Therapeutics. SK has received educational honoraria from Medeor Therapeutics. LM is an employee of Medeor Therapeutics. DBK has received grant\u00a0support to the University of Wisconsin from Medeor Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}